Sanne de Bruin

83 Transfusion practice in the bleeding critically ill; an international online survey – The TRACE-2 Survey Table S1. Difference between respondents with and without a massive transfusion protocol (continued) Massive transfusion protocol (N= 209) No massive transfusion protocol (N= 192) P-value Nothing 3(1%) 3(2%) 1 What guides your use of fibrinogen in critically ill patients with massive bleeding? I administer fibrinogen after lab testing (fibrinogen level) 67(32%) 79(41%) 0.331 I administer fibrinogen after viscoelastic testing (TEG/ROTEM) 41(20%) 37(19%) I empirically administer fibrinogen 26(12%) 17(9%) I empirically administer fibrinogen, but start titrating when first lab results are available 69(33%) 52(27%) Other 6(3%) 6(3%) What guides your use of prothrombin complex (Cofact, Octoplex,Beriplex) in critically ill patients with massive bleeding. I administer prothrombin complex after lab testing (PT/INR) 77(37%) 80(42%) 0.494 I administer prothrombin complex after viscoelastic testing (TEG/ROTEM) 54(26%) 37(19%) I empirically administer prothrombin complex 14(7%) 10(5%) I empirically administer prothrombin complex, but start titrating when first lab results are available 44(21%) 41(21%) 3